$2.8 Billion is the total value of HealthCor Management, L.P.'s 56 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 55.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| UNH | Sell | UNITEDHEALTH GROUP INC | $87,818,000 | +2.7% | 298,720 | -24.1% | 3.13% | -3.1% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $86,730,000 | -35.6% | 806,864 | -46.0% | 3.09% | -39.2% |
| ZBH | Sell | ZIMMER BIOMET HLDGS INC | $66,909,000 | -32.6% | 447,012 | -38.2% | 2.39% | -36.4% |
| XENT | Sell | INTERSECT ENT INC | $63,165,000 | +46.1% | 2,536,760 | -0.2% | 2.25% | +37.9% |
| BMY | Sell | BRISTOL MYERS SQUIBB CO | $53,920,000 | -4.9% | 840,000 | -24.8% | 1.92% | -10.2% |
| DHR | Sell | DANAHER CORPORATION | $50,490,000 | -49.1% | 328,970 | -52.1% | 1.80% | -52.0% |
| ISRG | Sell | INTUITIVE SURGICAL INC | $49,391,000 | -61.1% | 83,550 | -64.5% | 1.76% | -63.3% |
| MRK | Sell | MERCK & CO INC | $48,495,000 | -63.0% | 533,210 | -65.8% | 1.73% | -65.1% |
| CHNG | Sell | CHANGE HEALTHCARE INC | $46,706,000 | -9.1% | 2,849,650 | -33.0% | 1.67% | -14.3% |
| EW | Sell | EDWARDS LIFESCIENCES CORP | $31,077,000 | -77.4% | 133,210 | -78.7% | 1.11% | -78.7% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $26,733,000 | -44.7% | 175,000 | -52.1% | 0.95% | -47.8% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $24,717,000 | -44.8% | 308,538 | -49.4% | 0.88% | -47.9% |
| GILD | Sell | GILEAD SCIENCES INC | $18,423,000 | -39.8% | 283,520 | -41.3% | 0.66% | -43.2% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $14,420,000 | -87.5% | 65,860 | -90.3% | 0.51% | -88.2% |
| SYK | Sell | STRYKER CORP | $13,472,000 | -28.5% | 64,170 | -26.3% | 0.48% | -32.4% |
| PSNL | Exit | PERSONALIS INC | $0 | – | -283,500 | -100.0% | -0.16% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -316,679 | -100.0% | -0.17% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -1,491,376 | -100.0% | -0.22% | – |
| STML | Exit | STEMLINE THERAPEUTICS INC | $0 | – | -1,243,780 | -100.0% | -0.49% | – |
| SEM | Exit | SELECT MED HLDGS CORP | $0 | – | -824,900 | -100.0% | -0.52% | – |
| GMAB | Exit | GENMAB A Ssponsored ads | $0 | – | -696,835 | -100.0% | -0.53% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -282,090 | -100.0% | -0.56% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -300,905 | -100.0% | -0.72% | – |
| QGEN | Exit | QIAGEN NV | $0 | – | -614,110 | -100.0% | -0.76% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -400,000 | -100.0% | -0.77% | – |
| ALC | Exit | ALCON INC | $0 | – | -558,940 | -100.0% | -1.23% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORP | $0 | – | -961,820 | -100.0% | -1.48% | – |
| WMGI | Exit | WRIGHT MED GROUP N V | $0 | – | -2,062,360 | -100.0% | -1.61% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -756,400 | -100.0% | -2.39% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB LTD | $0 | – | -2,628,840 | -100.0% | -2.71% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -356,860 | -100.0% | -3.14% | – |
| CVRS | Exit | CORINDUS VASCULAR ROBOTICS I | $0 | – | -19,981,655 | -100.0% | -3.23% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -1,032,820 | -100.0% | -3.42% | – |
| BIIB | Exit | BIOGEN INCcall | $0 | – | -550,000 | -100.0% | -4.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.